Biosimilar Antibodies

The Anti-CLEC7A Antibody is a humanized monoclonal antibody produced in Chinese hamster ovary (CHO) cells, specifically designed to target CLEC7A (C-type lectin domain family 7 member A). This antibody has a predicted molecular weight of 150 kDa. For isotype control, it is recommended to use Human IgG4 kappa, Isotype Control, which serves as a standard in experiments to help distinguish specific from non-specific binding. This product is essential for researchers focusing on the role of CLEC7A in immune response and its implications in various inflammatory and infectious diseases.

Vapaliximab (2D10) is a monoclonal antibody specifically designed to target and bind to human vascular adhesion protein-1 (VAP-1). This antibody is utilized primarily in research focused on inflammatory processes and vascular biology, providing insights into the role of VAP-1 in disease mechanisms and potential therapeutic interventions.

AMG-820 is a fully human monoclonal antibody of the IgG2 isotype specifically designed to target CSF-1R (Colony Stimulating Factor 1 Receptor). This antibody effectively blocks the binding of its natural ligands, CSF1 and IL34, thereby inhibiting receptor activation induced by these ligands. For experimental control purposes, the Human IgG2 kappa, Isotype Control is recommended as a suitable isotype control for AMG-820. This product is essential for research focused on the modulation of CSF-1R activity, particularly in studies related to inflammation and cancer where CSF-1R plays a critical role.

Abrezekimab (VR 942), featuring CDP7766, is a humanized, high-affinity monoclonal antibody fragment with neutralizing properties against human interleukin-13 (IL-13). It specifically binds to IL-13, effectively preventing interaction with the IL-13Rα1 receptor subunit. This antibody is primarily utilized in asthma research to investigate the role and therapeutic potential of IL-13 inhibition in disease pathogenesis and progression.

Efpegsomatropin is a conjugate composed of human growth hormone linked to an Fc peptide, designed to enhance molecular stability and extend serum half-life. This conjugate is ideal for use in a range of biochemical studies, including investigations into growth hormone signaling pathways and the pharmacokinetics of peptide hormones. Its unique structure makes it a valuable tool for researchers studying the regulation of growth and metabolism.

Gentulizumab (Gensci-059) is a humanized IgG4 monoclonal antibody specifically designed to target CD47. This antibody demonstrates robust binding affinity for CD47 across both human and monkey tissues, effectively disrupting the CD47-SIRPα interaction. Such inhibition plays a critical role in modulating antitumor immunity, making Gentulizumab a potent agent for antitumor activity studies. For experimental control purposes, Human IgG4 (S228P) kappa serves as the appropriate isotype control for Gentulizumab.

Ersodetug is a human IgG2 κ monoclonal antibody targeting the insulin receptor (INSR). For experimental control purposes, it is recommended to use Human IgG2 kappa as an isotype control.

Rozanolixizumab (UCB7665) is a humanized, high-affinity monoclonal antibody targeting the human neonatal Fc receptor (FcRn). Classified as an IgG4P isotype, this antibody is primarily utilized in research focused on the reduction of pathogenic IgG in various autoimmune and alloimmune disorders. Its specific interaction with FcRn highlights its potential for modulating immune responses and antibody recycling, making it a valuable tool for studies in immunology and therapeutic development.

REGN5054 is a fully human monoclonal IgG1 antibody designed to bind specifically to CD8 antigens expressed on T cells in both human and cynomolgus models. This antibody provides a valuable tool for the study of T-cell function and the role of CD8 in immune responses.

Indemakitug is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets interferon-gamma (IFNG). For experimental control purposes, it is recommended to use Human IgG1 lambda2 as an isotype control.

The Anti-TPBG Antibody (PF-06263507) is a humanized monoclonal antibody, produced in Chinese Hamster Ovary (CHO) cells, designed to specifically target TPBG. This antibody is comprised of a human IgG1 type heavy chain and a human kappa type light chain, with an estimated molecular weight of 145.8 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody serves as a valuable tool for research focused on the biological functions and pathological roles of TPBG.

Mibavademab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting LEPR/CD295. This antibody is comprised of a human IgG4SP heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 145.58 kDa. For experimental control purposes, the appropriate isotype control is Human IgG4 kappa.

Citatuzumab bogatox (VB6-845) is a recombinant immunotoxin consisting of a humanized antibody Fab fragment targeting epithelial cell adhesion molecule (EpCAM) linked to a modified cytotoxin, bouganin. This agent binds selectively to EpCAM-positive cell lines, inducing apoptosis effectively. Citatuzumab bogatox demonstrates robust activity in EpCAM-positive human tumor xenograft models, highlighting its potential for targeted cancer therapy applications.

Lebrikizumab (TNX-650) is a humanized IgG4 monoclonal antibody that targets interleukin-13 (IL-13), binding specifically to a non-receptor binding domain of IL-13 to inhibit its activity. This antibody effectively blocks the IL-13-driven Th2 inflammatory response by interfering with the signaling pathway involving IL-4Rα/IL-13Rα1. Lebrikizumab also exhibits anti-itch properties, making it a valuable tool for research into asthma, atopic dermatitis, and neuroinflammatory disorders.

The Anti-PTPRC/CD45 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the protein tyrosine phosphatase receptor type C (PTPRC), also known as CD45. This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended. This antibody is essential for research focusing on immune cell signaling and function, as CD45 is pivotal in activating and regulating T and B cell receptor signaling pathways.

Cenvacibart is a monoclonal antibody designed to inhibit coagulation factor XI (F11), a key protein in the coagulation cascade. By targeting and blocking the activity of factor XI, Cenvacibart effectively reduces thrombus formation. This antibody is particularly valuable in the study of thrombotic disorders, offering a promising tool for researchers exploring the mechanisms and potential treatments of these conditions.

Zampilimab (UCB-7858) is a monoclonal antibody specifically targeting transglutaminase 2 (TG2). This antibody demonstrates potential utility in enhancing the outcomes of renal transplantation. Zampilimab has been developed to modulate immune responses, potentially reducing the risk of transplant rejection and improving graft survival. Its precise mechanism involves the inhibition of TG2, an enzyme implicated in inflammation and tissue fibrosis. This product is pivotal for research focused on transplant immunology and the development of therapeutic strategies to increase transplant success rates.

Atigotatug is a humanized IgG1κ monoclonal antibody specifically targeting Fucosyl ganglioside GM1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Apamistamab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting PTPRC/CD45. This antibody is composed of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, exhibiting a predicted molecular weight of 146.52 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended.

Fezakinumab is a monoclonal antibody targeting interleukin-22 (IL-22), designed for the investigation of inflammatory conditions including psoriasis and rheumatoid arthritis. This antibody binds specifically to IL-22, a cytokine involved in the regulation of inflammatory responses, offering a valuable tool for researchers studying the pathophysiology and potential therapeutic interventions for these diseases.

Puxitatug is a monoclonal antibody of the immunoglobulin G1-κ class, specifically targeting the human VTCN1 protein, also known as V-set domain-containing T cell activation inhibitor 1, B7 family member H4, B7H4, and B7-H4. This antibody binds selectively to VTCN1, a negative regulator of T cell-mediated immune responses, making it a valuable tool for research in immunology and oncology.

Otlertuzumab (TRU-016) is a humanized monoclonal antibody targeting CD37, designed for use in cancer research. This antibody selectively binds to the CD37 antigen, a protein predominantly expressed on the surface of B cells, making it a valuable tool for studying B-cell malignancies. Otlertuzumab is utilized in various experimental settings to investigate its potential as a therapeutic agent in treating hematological cancers.

Crenezumab (MABT 5102A; RG 7412) is a fully humanized monoclonal antibody designed to target and bind various forms of amyloid beta (Aβ), including soluble, oligomeric, and fibrillar aggregates. This antibody is extensively utilized in the study of Alzheimer's disease, providing a critical tool for researchers investigating the pathogenesis and potential therapeutic interventions for this neurodegenerative disorder.

AMG 305 represents an innovative dual-targeting BiTE (bispecific T-cell engager) molecule, specifically engineered with a half-life extended (HLE) format. This molecule uniquely targets both P-cadherin (CDH3) and mesothelin (MSLN) on tumor cells, in addition to CD3 on T-cells. The design of AMG 305 aims to enhance the therapeutic index in solid tumors by selectively engaging T-cells to tumor cells that co-express CDH3 and MSLN, while minimizing interaction with normal cells that express only one of these antigens. This selective mechanism of action positions AMG 305 as a promising candidate for targeted cancer therapy, especially in settings where both CDH3 and MSLN are overexpressed.

Alirocumab is a human monoclonal antibody that targets and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, Alirocumab enhances the liver's capacity to bind and clear low-density lipoprotein cholesterol (LDL-C) from the bloodstream, thereby significantly reducing circulating levels of LDL-C. Additionally, Alirocumab modulates various inflammatory pathways, including the reduction of NLRP3 inflammasome activity and regulation of the Nrf2/HO-1, HMGB1/NF-κB, and Fractalkine/CX3CR1 signaling pathways. These mechanisms contribute to its therapeutic effects in improving atherosclerosis and reducing inflammation. Alirocumab is primarily used in research focused on lipid metabolism disorders, cardiovascular diseases, and inflammatory response modulation.

Gatipotuzumab (PankoMab) is a humanized monoclonal antibody designed to specifically recognize a tumor-specific epitope of mucin-1 (TA-MUC1). This antibody demonstrates potent tumor-specific activity through antibody-dependent cell-mediated cytotoxicity (ADCC), making it a valuable tool for targeted cancer therapy research.

BMS-986021, also known as BMS-986148 antibody, is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets Mesothelin, a protein frequently overexpressed in various forms of cancer, making it a valuable tool for oncological research. This antibody comprises a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 144.46 kDa. For experiments requiring an isotype control, the Human IgG1 kappa Isotype Control is recommended to accurately assess the antibody's specificity and ensure robust experimental results.

The Anti-DC-SIGN/CD209 Antibody is a humanized antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target DC-SIGN/CD209. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of approximately 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for researchers focusing on cellular signaling, immune response modulation, and pathogen recognition studies involving DC-SIGN/CD209.

Ucenprubart is a human IgG4κ monoclonal antibody targeting CD200R1. For optimal experimental control, it is recommended to use Human IgG4 kappa as an isotype control.

Maslimomab is a murine-derived monoclonal antibody specifically designed to target the T-cell receptor. This antibody functions as an immunosuppressive agent, making it a valuable tool for research into T-cell mediated immune responses and potential therapeutic applications in immune-related disorders.

Enlimomab (BI-RR 0001) is a murine IgG2a monoclonal antibody that targets human Intercellular Adhesion Molecule 1 (ICAM-1). This antibody functions by inhibiting leukocyte adhesion to vascular endothelium, effectively reducing leukocyte extravasation and subsequent inflammatory tissue damage. Due to its anti-inflammatory properties, Enlimomab is particularly useful in research focused on stroke and related inflammatory processes.

Alnuctamab (EM901) is a humanized, asymmetric two-arm immunoglobulin G (IgG) T-cell engager (TCE) designed to facilitate targeted immune responses. This bi-specific antibody selectively binds to the B-cell maturation antigen (BCMA) and CD3, a critical component of the T-cell receptor complex. Alnuctamab is primarily utilized in immunological research to study and manipulate T-cell mediated responses against cells expressing BCMA, making it a valuable tool in the investigation of immune therapies.

Bavunalimab is a bispecific monoclonal antibody targeting CTLA-4 and LAG-3, designed for the dual inhibition of these immune checkpoint inhibitors. This humanized antibody promotes T-cell activation, demonstrated in NSG mouse models, making it a valuable tool for investigating immune responses in oncology research. Bavunalimab is specifically developed for studies focusing on the modulation of immune checkpoints in cancer therapy.

MEDI-1814 is a fully human IgG1 monoclonal antibody designed to target the C-terminus of amyloid beta (Aβ) 42 peptide. This antibody specifically binds to circulating Aβ peptides, facilitating their removal and preventing their aggregation into neurotoxic oligomers. MEDI-1814 is primarily utilized in research focused on the pathogenesis and potential treatments of Alzheimer's disease. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Romlusevimab (BRII-198) is a recombinant human IgG1 monoclonal antibody designed to specifically neutralize the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This targeted mechanism of action facilitates the inhibition of viral entry into host cells, offering potential therapeutic benefits in the treatment and prevention of COVID-19. Romlusevimab’s specificity and neutralizing capability make it a valuable tool in coronavirus research and therapeutic development.

Danvilostomig is a monoclonal antibody designed to target CTLA4 and PDCD1, key immune checkpoint proteins. This antibody is utilized in the study of immune checkpoint regulation and has potential applications in immunotherapy research, particularly in the context of cancer and autoimmune diseases. Danvilostomig's dual specificity allows for comprehensive investigation into the mechanisms of T-cell regulation and immune tolerance.

Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular domain of glycoprotein NMB (GPNMB), which is overexpressed in certain human breast cancers and melanomas. This antibody can be conjugated with the cytotoxic drug monomethyl auristatin E to create glembatumumab vedotin, an antibody-drug conjugate (ADC) designed to deliver antitumor agents directly to cancer cells. Glembatumumab vedotin demonstrates significant antitumor activity by exploiting the specificity of the antibody to direct cytotoxic activity to GPNMB-expressing tumor cells, thereby minimizing systemic toxicity. This mechanism positions it as a promising therapeutic option in the treatment of GPNMB-expressing malignancies.

Praluzatamab is a monoclonal antibody specifically designed to target the activated leukocyte cell adhesion molecule (ALCAM), also known as CD116. This antibody has been engineered to facilitate the development of antibody-drug conjugates, such as Praluzatamab ravtansine, enhancing its utility in targeted cancer therapy. Praluzatamab is primarily utilized in oncological research, where it serves as a critical tool in the investigation of cancer pathogenesis and the development of novel therapeutic strategies.

Rademikibart (CBP-201) is a human monoclonal antibody specifically designed to target IL-4Rα, exhibiting a high binding affinity with a dissociation constant (K_D) of 20.7 pM for human IL-4Rα epitopes. This antibody is characterized by its species specificity, as it does not interact with IL-4Rα from non-human species. Rademikibart effectively inhibits both IL-4 and IL-13-mediated STAT6 signaling pathways, as well as TF-1 cell proliferation and TARC production in peripheral blood mononuclear cells (PBMCs). This antibody is particularly relevant for research into moderate-to-severe Th2-mediated inflammatory diseases, providing a valuable tool for elucidating disease mechanisms and potential therapeutic targets.

Urabrelimab (SRF231) is a fully human monoclonal antibody targeting CD47. It effectively inhibits the interaction between CD47 and signal-regulatory protein alpha (SIRPα), a critical pathway involved in evading phagocytosis by immune cells. This blockade can promote the engulfment and elimination of cancer cells, making it a valuable tool for oncology research.

Camoteskimab (AVTX-007) is a fully humanized, high-affinity monoclonal antibody targeting interleukin-18 (IL-18). By specifically binding to IL-18, Camoteskimab effectively inhibits the interaction between IL-18 and its receptor, thereby modulating the inflammatory response. This antibody is particularly valuable in research focused on cardiovascular and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma, providing a potent tool for investigating the pathological roles of IL-18 in these conditions.

Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC.

Serplulimab (HLX10) is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. This antibody is designed for use in research focused on small cell lung cancer, providing a valuable tool for investigating the role of the PD-1/PD-L1 pathway in cancer immunology and potential therapeutic interventions.

Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody that specifically targets the fibroblast activation protein (FAP). This antibody is utilized in research focusing on colorectal cancer and non-small cell lung cancer (NSCLC), providing a valuable tool for investigating the role of FAP in tumor progression and response to therapy.

The Anti-PCSK9 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 145 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This antibody is ideal for research focused on the regulation of LDL cholesterol levels and cardiovascular disease mechanisms.

GSK-2330811 is a humanized IgG1 monoclonal antibody specifically designed to target Oncostatin M (OSM). This antibody is primarily utilized in research focused on diffuse cutaneous systemic sclerosis (dcSSc). For experimental control purposes, Human IgG1 kappa serves as the appropriate isotype control for GSK-2330811.

Quetmolimab is a humanized monoclonal antibody targeting CX3CL1, a chemokine known for its role in modulating chemotaxis and cell adhesion. This antibody is designed for precision in binding and neutralizing CX3CL1, making it a valuable tool for research into inflammatory responses and immune cell migration.

Izastobart is a human IgG1 λ2 monoclonal antibody targeting C5AR1. For accurate experimental controls, it is recommended to use Human IgG1 lambda2 as an isotype control.

Maridebart is a monoclonal antibody of the human immunoglobulin G1-kappa subclass, specifically targeting the gastric inhibitory polypeptide receptor (GIPR). This antibody binds selectively to GIPR, a receptor involved in glucose homeostasis and lipid metabolism, making it a valuable tool for research in metabolic disorders and diabetes.

Ianalumab (FUT8-KO) is an anti-BAFF-R monoclonal antibody, produced in Chinese Hamster Ovary (CHO) cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). The absence of fucose on this antibody significantly enhances its Antibody-Dependent Cellular Cytotoxicity (ADCC) capabilities. This antibody effectively blocks the interaction between B-cell Activating Factor (BAFF) and its receptor BAFF-R, thereby inhibiting the BAFF-mediated apoptotic protection. This makes Ianalumab (FUT8-KO) a valuable tool for research into BAFF-R related signaling pathways and potential therapeutic interventions in autoimmune diseases and malignancies where BAFF and BAFF-R interactions play a critical role.